Immuneering annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Immuneering Capital Expenditures (CapEx) Growth & History (IMRX)
Immuneering's capital expenditures (capex) was $142,226 for fiscal 2025.
View full Immuneering company overviewImmuneering annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $142,226 | $57,351 | +67.57% |
| 2024 | 2024-12-31 | $84,875 | −$257,871 | −75.24% |
| 2023 | 2023-12-31 | $342,746 | −$399,737 | −53.84% |
| 2022 | 2022-12-31 | $742,483 | $681,697 | +1121.47% |
| 2021 | 2021-12-31 | $60,786 | $7,371 | +13.80% |
| 2020 | 2020-12-31 | $53,415 | — | — |
Immuneering quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27,367 | $25,251 | +1193.34% |
| Q1 2026 | 2026-03-31 | $79,930 | $70,985 | +793.57% |
| Q4 2025 | 2025-12-31 | $123,910 | $114,554 | +1224.39% |
| Q3 2025 | 2025-09-30 | $7,255 | $1,987 | +37.72% |
| Q2 2025 | 2025-06-30 | $2,116 | −$30,657 | −93.54% |
| Q1 2025 | 2025-03-31 | $8,945 | −$28,533 | −76.13% |
| Q4 2024 | 2024-12-31 | $9,356 | −$161,562 | −94.53% |
| Q3 2024 | 2024-09-30 | $5,268 | −$51,881 | −90.78% |
| Q2 2024 | 2024-06-30 | $32,773 | −$53,913 | −62.19% |
| Q1 2024 | 2024-03-31 | $37,478 | $9,485 | +33.88% |
| Q4 2023 | 2023-12-31 | $170,918 | $101,616 | +146.63% |
| Q3 2023 | 2023-09-30 | $57,149 | −$335,985 | −85.46% |
| Q2 2023 | 2023-06-30 | $86,686 | −$78,311 | −47.46% |
| Q1 2023 | 2023-03-31 | $27,993 | −$87,057 | −75.67% |
| Q4 2022 | 2022-12-31 | $69,302 | $56,250 | +430.97% |
| Q3 2022 | 2022-09-30 | $393,134 | $381,788 | +3364.96% |
| Q2 2022 | 2022-06-30 | $164,997 | $145,173 | +732.31% |
| Q1 2022 | 2022-03-31 | $115,050 | $98,486 | +594.58% |
| Q4 2021 | 2021-12-31 | $13,052 | — | — |
| Q3 2021 | 2021-09-30 | $11,346 | $5,743 | +102.50% |
| Q2 2021 | 2021-06-30 | $19,824 | — | — |
| Q1 2021 | 2021-03-31 | $16,564 | — | — |
| Q3 2020 | 2020-09-30 | $5,603 | — | — |
Immuneering capital expenditures (capex) trends
Over the last five fiscal years, Immuneering's capital expenditures (capex) increased from $53,415 to $142,226, a change of $88,811. The latest reported quarter, Q2 2026, shows $27,367.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗